Colaboración ofertada

  •  A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome (GRACE) (estudio clínico comercial)

https://clinicaltrials.gov/ct2/show/NCT03697109?term=NCT03697109&cntry=ES&draw=2&rank=1

Pacientes identificados a nivel interprovincial: 1

  • This Phase 3 study patients will be randomized in a 1:1 ratio to treatment with relacorilant (active drug) or placebo. Patients will receive relacorilant or placebo for 22 weeks. Patients who complete the study may also be eligible to roll over into an extension study (GRADIENT) (estudio clínico comercial)

https://www.clinicaltrials.gov/ct2/show/NCT04652726?term=orion-16+inclisiran&draw=2&rank=1

Pacientes identificados a nivel interprovincial: 7 Pacientes randomizados: 3

  •  A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS) (CS3) (estudio clínico comercial)

https://clinicaltrials.gov/ct2/show/NCT04568434?term=ISIS678354-CS3&draw=2&rank=1

  •  A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (CS5) (estudio clínico comercial)

https://clinicaltrials.gov/ct2/show/NCT05079919?term=NCT05079919&draw=2&rank=1

  •  A Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) (estudio clínico comercial)

https://clinicaltrials.gov/ct2/show/NCT05030428?term=NCT05030428&draw=2&rank=1

Pacientes identificados a nivel interprovincial: 1 Pacientes randomizados: 1

  •  A Phase 3, International, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on CKD Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia (STABILIZE CKD) (estudio clínico comercial)

https://clinicaltrials.gov/ct2/show/NCT05056727?term=NCT05056727&draw=2&rank=1

  •  A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment (HAC) (estudio clínico comercial)

https://clinicaltrials.gov/ct2/show/NCT04490915?term=NBI-74788-CAH3003&draw=2&rank=1

Pacientes identificados a nivel interprovincial: 1 Pacientes randomizados: 1

  •  Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Heterozygous FH Patients on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction (LIB003-004) (estudio clínico comercial)

https://clinicaltrials.gov/ct2/show/NCT04797104?term=LIB003-004&draw=2&rank=1

Pacientes identificados a nivel interprovincial: 2 Pacientes randomizados: 1

  •  A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults With Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype (Diagnod 3) (estudio clínico comercial)

https://clinicaltrials.gov/ct2/show/NCT05018585?term=D%2FP3%2F21%2F7&draw=2&rank=1

Pacientes identificados a nivel interprovincial: 1 Pacientes randomizados: 1

  •  A Randomised, Double-Blind, Placebo-Controlled, Dose-Response Study of the Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy (estudio clínico comercial)

https://www.clinicaltrials.gov/ct2/show/NCT03755934?term=NCT03755934&draw=2&rank=1

  • A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome (estudio clínico comercial)

https://clinicaltrials.gov/ct2/show/NCT05322096?term=RGH-706-003&draw=2&rank=1

 

  • Proyecto unicéntrico independiente. HAE: Caracterización clínica de sujetos con hiperalfalipoproteinemía extrema e identificación de variantes de secuencia en genes candidatos. IP: María José Ariza Cobos (UGC Medicina Interna, H Universitario Virgen de la Victoria)
  • Proyecto unicéntrico independiente. Quilomicronemia: Aplicación de métodos de secuenciación de nueva generación o NGS para el diagnóstico molecular del síndrome de quilomicronemia familiar. IP: María José Ariza Cobos (UGC Medicina Interna, H Universitario Virgen de la Victoria)
  • Proyecto unicéntrico independiente. ITI 2019-0033: Avance hacia nuevas alternativas terapéuticas en la miocardiopatía dilatada a través de los RNA no codificados. IP: Rocío Toro Cebada (UGC Medicina Interna, H. Universitario Puerta del Mar)